首页>投融资
Maxim Biomedical
股权融资
Maxim Biomedical是一家位于美国的生物技术公司,专注于开发创新的生物医学解决方案。该公司的业务涉及生物药物、医疗器械和诊断试剂的研发和生产。Maxim Biomedical在肿瘤治疗、神经退行性疾病和再生医学等领域具有独特的研究优势,致力于开发能够改善患者生活质量的新型生物药物和医疗器械。此外,该公司还积极开展国际合作和技术转让,推动生物医学领域的全球发展
基本信息
-
公司全称Maxim Biomedical Inc
-
类型医疗诊断产品开发商
-
产业领域试剂/耗材、器械/设备
-
公司人数15~50人
-
地址1500 East Gude Drive ROCKVILLE MARYLAND 20850; US; Telephone: +13012510800; Fax: +13017621542;
-
联系电话13012510800
-
邮箱info@mbidiagnostic.com
-
成立时间2005-01-01
投融资
-
2024-07-29股权融资未透露CTM Investments
相关投融资企业
收并购
Becton, Dickinson and Co is a medical technology company with a particular emphasis on diagnostics and disposables.In July 2022, Becton, Dickinson and Co acquired MedKeeper.In April 2022, Becton, Dickinson and Co had completed its spinoff of Embecta Corp.In February 2022, Becton, Dickinson and Co had announced the sale of Cytognos by Vitro SA. Later that month, the company acquired Cytognos Sl completely.In December 2021, the company had acquired Tissuemed Ltd. Later that month, the company announced it completed the acquisition of Scanwell Health Inc.In November 2020, BD had acquired the medical business assets of CUBEX.In September 2018, Thermo Fisher Scientific had entered into a definitive agreement to acquire advanced bioprocessing business of BD Technologies.In July 2005, Becton Dickinson had agreed to sell its Clontech Laboratories Inc unit to Takara Bio for $60 million, The plan to sell Clontech had a
增发
Establishment Labs Holdings Inc.于2013年10月9日在英属维尔京群岛的母公司控制下重组。该公司是一家医疗技术公司,专注于改善患者的安全和美学结果,最初是在乳房美学和重建市场。公司的硅胶填充乳房植入物系列,品牌为Motiva Implants,是医疗技术平台的核心。该公司还开发了其他补充产品和服务,旨在进一步提高患者的治疗效果。
B轮
星辰海医疗成立于2020年10月,是一家专注于内窥镜介入诊疗业务的医疗科技公司,旨在向全球提供涵盖泌尿、呼吸、消化等科室的内窥镜介入诊疗整体解决方案,让疾病更早被发现,让患者更好被治疗。内窥镜诊疗是非血管微创介入的重要组成部分,广泛分布于消化科、泌尿科、呼吸、耳鼻喉科、普外科以及妇科等。